Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis for DGX:

Technical Analysis

• Current price: $174.875 (Regular market, +1.53%)
• Strong upward momentum with RSI-14 at 70.76, indicating slightly overbought conditions
• MACD is positive (4.18) with bullish divergence (0.73)
• Trading above all major moving averages (5,10,20,60,200-day)

Recent Developments

• Quest Diagnostics announced acquisition of select assets from Fresenius Medical's Spectra Laboratories, expanding their renal testing capabilities
• Deal expected to close in H2 2025 with service transition completion by early 2026
• Recent insider selling activity: SVP & General Counsel sold 604 shares, with no insider purchases in past 6 months

Analyst Sentiment

• Mixed analyst ratings with recent price targets:
  • Piper Sandler: Hold, PT $180
  • Evercore ISI: Hold, PT $175
  • Bank of America: Buy, PT $190

Recommendation SELL at current levels ($174.875) based on:

• Overbought technical indicators
• Recent insider selling pattern
• Trading near analyst price targets
• Mixed institutional sentiment with more institutions reducing positions (410) than increasing (377)

Based on the provided data and recent analyst reports, here's a price prediction analysis for DGX stock in 2025:

Technical Analysis

The stock is currently trading at $174.875 during regular market hours on February 24, 2025, showing a +1.53% increase. Technical indicators suggest a bullish momentum:

• RSI-14 at 70.76 indicates strong momentum but approaching overbought territory
• MACD is positive with bullish divergence (MACD: 4.18, Signal: 3.45)
• Stock trading above all major moving averages (SMA 20: 164.54, SMA 60: 158.28)

Price Target Analysis

Recent analyst price targets from January 2025:

• Truist: $182 (raised from $172)
• Barclays: $175 (raised from $168)
• Mizuho Securities: Maintains Buy rating with implied upside
• Jefferies: $190 price target

Fundamental Drivers

Key catalysts supporting higher prices:

• Revenue guidance of $10.7B-$10.85B for 2025
• Expected 3% organic revenue growth
• Strong Advanced Diagnostics segment with double-digit growth
• Strategic acquisitions contributing to growth
• Expanded health plan partnerships covering 90% of US market

2025 Price Prediction

Based on technical and fundamental analysis:

Base Case ($175-185): 60% probability

• Driven by organic growth and acquisition synergies
• Supported by current analyst targets
• Assumes successful execution of strategic initiatives

Bull Case ($185-195): 25% probability

• Exceeding revenue guidance
• Higher-than-expected margin expansion
• Additional strategic acquisitions

Bear Case ($155-165): 15% probability

• Market volatility impact
• Integration challenges with acquisitions
• Margin pressure from investments

Most likely scenario: Base case with price target of $180 by end of 2025, supported by strong fundamentals and positive analyst sentiment.

The S1 support level for DGX Stock is $165.84 ,The R1 resistant level for DGX Stock is $175.24.

As of the end of day on 2025-02-27, the price of DGX Stock was $171.745.

The target price for DGX Stock according to analyst rating is 180.42, with the highest price target at 190.00 and the lowest at 170.00. Analysts have a Moderate Buy rating on DGX Stock overall.

The market cap of DGX is $19.3B.

Based on the provided data and current market conditions, here's a concise analysis of DGX's valuation:

Technical Analysis

• DGX is showing strong momentum with RSI at 70.76 and trading above all major moving averages (5,10,20,60,200-day)
• Currently trading at $174.85, up 1.52% in regular market session
• Bollinger Band analysis shows price near upper band with 0.76 bandwidth, indicating potential overbought conditions

Fundamental Valuation

• Forward P/E of 18.33x is reasonable compared to historical average of 19.60x
• EV/EBITDA of 11.19x suggests fair valuation relative to peers
• Price-to-Sales ratio decreased from 1.87x to 1.68x year-over-year

Recent Developments

• Announced acquisition of select assets from Fresenius Medical's Spectra Laboratories, expanding renal testing capabilities
• Strong Q4 2024 performance with 15% revenue growth including 5% organic growth
• Institutional investors showing mixed sentiment with 377 increasing positions while 410 reducing

Conclusion DGX appears fairly valued at current levels considering:

• Strong technical momentum but approaching overbought territory
• Reasonable valuation metrics relative to historical levels
• Positive business expansion through strategic acquisitions
• Solid organic growth in core business segments

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.

Based on the available data and recent analyst reports, here's a projection for DGX stock price in 2030:

Quest Diagnostics (DGX) stock is projected to reach $245-255 by 2030. This forecast is supported by the company's strategic expansion in specialized testing services, successful M&A activities including the recent Spectra Laboratories acquisition, and consistent revenue growth in high-margin testing areas. The company's strong market position in diagnostic testing services and continued focus on operational efficiency suggest a compound annual growth rate (CAGR) of approximately 6.5-7% through 2030.

DGX has a total of 40000 employees.